Improved (223)Ra Therapy with Combination Epithelial Sodium Channel Blockade

[(223)Ra]RaCl(2) is the first approved α-particle–emitting therapy and is indicated for treatment of bone metastatic castration-resistant prostate cancer. Approximately half the dose is absorbed into the gastrointestinal tract within minutes of administration, limiting disease-site uptake and contri...

Descripción completa

Detalles Bibliográficos
Autores principales: Abou, Diane S., Fears, Amanda, Summer, Lucy, Longtine, Mark, Benabdallah, Nadia, Riddle, Ryan C., Ulmert, David, Michalski, Jeff M., Wahl, Richard L., Chesner, Denise, Doucet, Michele, Zachos, Nicholas C., Simons, Brian W., Thorek, Daniel L.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2021
Materias:
Featured Basic Science Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612198/
https://www.ncbi.nlm.nih.gov/pubmed/33837069
http://dx.doi.org/10.2967/jnumed.121.261977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612198/
https://www.ncbi.nlm.nih.gov/pubmed/33837069
http://dx.doi.org/10.2967/jnumed.121.261977

Ejemplares similares